Skip to main content
SpringerLink
Log in

Altered FDG uptake patterns in pediatric lymphoblastic lymphoma patients receiving induction chemotherapy that includes very high dose corticosteroids

  • Original Article
  • Published:
Pediatric Radiology Aims and scope Submit manuscript

Abstract

Background

Altered FDG uptake patterns were noted in certain lymphoblastic lymphoma patients during therapy.

Objective

To describe these altered FDG uptake patterns and their relationship to chemotherapy.

Materials and methods

Thirty-five FDG PET or PET/CT scans obtained in 11 children with lymphoblastic lymphoma were retrospectively reviewed. FDG uptake patterns were recorded. SUV measurements were performed in liver and facial soft tissues. Results were correlated with induction chemotherapy regimens.

Results

Six of the children had transiently altered FDG uptake with increased uptake in the superficial soft tissues, most notably involving the face. Altered uptake was noted approximately 1 month after initiation of chemotherapy and subsequently resolved. Hepatic uptake was transiently reduced on the 1-month scan in all six children with increased facial uptake. No significant FDG uptake in lymphoma was seen on five of six scans with altered uptake; however, two of these five affected children had FDG uptake in lymphoma on the next follow-up examination. Blood glucose levels in the affected children were in the normal range. All six children with altered FDG uptake received the same induction chemotherapy regimen, which included very high doses of corticosteroids.

Conclusions

Children with lymphoblastic lymphoma on induction chemotherapy protocols including very high doses of corticosteroids transiently demonstrated altered FDG uptake patterns, including increased superficial facial uptake and reduced hepatic uptake. The facial uptake is probably the FDG PET equivalent of Cushingoid facies. Caution in interpreting scans with this altered FDG uptake pattern is suggested, as uptake at sites of lymphomatous involvement may potentially be affected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Shankar A, Fiumara F, Pinkerton R (2008) Role of FDG PET in the management of childhood lymphomas—case proven or is the jury still out? Eur J Canc 44:663–673

    Article  Google Scholar 

  2. Raef R, Omar W, Kotb M et al (2010) Role of PET/CT in malignant pediatric lymphoma. Eur J Nucl Med Mol Imag 37:319–329

    Article  Google Scholar 

  3. Jacene HA, Ishimori T, Engles JM et al (2006) Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med 47:950–956

    PubMed  CAS  Google Scholar 

  4. Kazama T, Swanston N, Podoloff DA et al (2005) Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imag 32:1406–1411

    Article  CAS  Google Scholar 

  5. Sugawara Y, Fisher SJ, Zasadny KR et al (1998) Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 16:173–180

    PubMed  CAS  Google Scholar 

  6. Yamane T, Daimaru O, Ito S et al (2004) Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas. J Nucl Med 45:1838–1842

    PubMed  Google Scholar 

  7. Ramadori G, Cameron S (2010) Effects of systemic chemotherapy on the liver. Ann Hepatol 9:133–143

    PubMed  CAS  Google Scholar 

  8. Matsumoto T, Yamasaki S, Arakawa A et al (2007) Exposure to a high total dosage of glucocorticoids produces non-alcoholic steatohepatitis. Pathol Int 57:388–389

    Article  PubMed  Google Scholar 

  9. Shigematsu A, Okada K, Abe N et al (2006) Non-alcoholic steatohepatitis occurring in a patient with T-lymphoblastic lymphoma during chemotherapy including prednisolone. Leuk Lymphoma 47:1397–1399

    Article  PubMed  Google Scholar 

  10. Candelli M, Nista EC, Pignataro G et al (2003) Steatohepatitis during methylprednisolone therapy for ulcerative colitis. J Intern Med 253:391–392

    Article  PubMed  CAS  Google Scholar 

  11. Dourakis SP, Sevastianos VA, Kaliopi P (2002) Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 97:1074–1075

    Article  PubMed  CAS  Google Scholar 

  12. Abele JT, Fung CI (2010) Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values. Radiology 254:917–924

    Article  PubMed  Google Scholar 

  13. Rabkin Z, Israel O, Zohar K (2010) Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysis. J Nucl Med 51:1015–1020

    Article  PubMed  Google Scholar 

  14. Diederichs CG, Staib L, Glatting G et al (1998) FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39:1030–1033

    PubMed  CAS  Google Scholar 

  15. Torizuka T, Zasadny KR, Wahl RL (1999) Diabetes decreases FDG accumulation in primary lung cancer. Clin Positron Imaging 2:281–287

    Article  PubMed  Google Scholar 

  16. Chang YC, Yen TC, Ng KK et al (2005) Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer? Eur J Nucl Med Mol Imag 32:647–652

    Article  Google Scholar 

  17. Gorenberg M, Hallett WA, O’Doherty MJ (2002) Does diabetes affect [18F]FDG standardized uptake values in lung cancer? Eur J Nucl Med Mol Imag 29:1324–1327

    Article  CAS  Google Scholar 

  18. Moreno-Fernandez J, Gutierrez-Alcantara C, Galvez Moreno A et al (2008) Corticotrophin-dependent Cushing syndrome due to sacrococcygeal teratoma detected by [18F]fluorodeoxyglucose positron emission tomography. J Clin Endocrinol Metab 93:3282–3283

    Article  PubMed  CAS  Google Scholar 

  19. Cho S, Ra YJ, Lee CT et al (2008) Difficulties in diagnosis and management of ectopic Cushing syndrome. J Thorac Oncol 3:444–446

    Article  PubMed  Google Scholar 

  20. Shah NA, Urusova IA, D’Agnolo A et al (2007) Primary hepatic carcinoid tumor presenting as Cushing’s syndrome. J Endocrinol Invest 30:327–333

    PubMed  CAS  Google Scholar 

  21. Hashiba T, Saitoh Y, Asanuma N et al (2006) Reduction of a pancreatic tumor after total removal of an ACTH secreting pituitary tumor: differential diagnosis of Cushing’s syndrome. Endocr J 53:203–208

    Article  PubMed  CAS  Google Scholar 

  22. Fasshauer M, Lincke T, Witzigmann H et al (2006) Ectopic Cushing syndrome caused by a neuroendocrine carcinoma of the mesentery. BMC Canc 6:108

    Article  Google Scholar 

  23. Kumar J, Spring M, Carroll PV et al (2006) 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin Endocrinol 64:371–374

    CAS  Google Scholar 

  24. Basu S, Nair N (2005) 18F-FDG uptake in bilateral adrenal hyperplasia causing Cushing’s syndrome. Eur J Nucl Med Mol Imag 32:384

    Article  Google Scholar 

  25. Markou A, Manning P, Kaya B et al (2005) [18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing’s syndrome. Eur J Endocrinol 152:521–525

    Article  PubMed  CAS  Google Scholar 

  26. Ahmed M, Imaddudin K, Alari A et al (2000) ACTH-producing pituitary cancer: experience at the King Faisal Specialist Hospital & Research Centre. Pituitary 3:105–112

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, MLC 5031, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH, 45229-3039, USA

    Susan E. Sharp & Michael J. Gelfand

  2. Division of Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

    Michael J. Absalon

Authors
  1. Susan E. Sharp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Gelfand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael J. Absalon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan E. Sharp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharp, S.E., Gelfand, M.J. & Absalon, M.J. Altered FDG uptake patterns in pediatric lymphoblastic lymphoma patients receiving induction chemotherapy that includes very high dose corticosteroids. Pediatr Radiol 42, 331–336 (2012). https://doi.org/10.1007/s00247-011-2228-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00247-011-2228-7

Keywords

Search

Navigation